BLACKLEDGER Selling Watch: RIVN, CCJ, UEC
BLACKLEDGER's latest selling watch update tracks RIVN, CCJ, UEC, CRSP, NTLA, COIN from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Selling Watch Data
The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-09-16T08:00:53.412717+00:00.
- RIVN (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- CCJ (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- UEC (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- CRSP (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NTLA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- COIN (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NFLX (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- SOFI (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
RIVN Public Research Bio
Name: Rivian Automotive, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Rivian Automotive, Inc., together with its subsidiaries, develops, manufactures, and sells category-defining electric vehicles. It operates through two segments, Automotive, and Software and Services. The company offers consumer vehicles, including a two-row, five-passenger pickup truck under the R1T brand; and a three-row, seven-passenger sport utility vehicle under the R1S name. It also provides software and services, such as vehicle electrical architecture and software development, as well as Autonomy+, r[redacted]rketing, vehicle repair and maintenance services, software subscriptions, vehicle accessories, financing, insurance, and other services. In addition, the company designs, develops, and manufactures the Rivian Adventure Network Direct Current fast chargers; and FleetOS, a proprietary, end-to-end centralized fleet management subscription platform. Further, it offers Rivian Commercial Van platform for Electric Delivery Van wit
- Latest public price/reference: $15.54
- Public market capitalization: $22.50B
- Recent public volume/reference: 21.08M
- One-month public movement: -1.4%
- Sector/category: Consumer Cyclical
Why RIVN Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Rivian Calls R2 Launch an Inflection Point as D[redacted]nd, Autonomy Plans Accelerate — MarketBeat
- Rivian Automotive (RIVN) Sees a More Significant Dip Than Broader Market: Some Facts to Know — Zacks
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More — 24/7 Wall St.
- The EV Bubble Has Burst. How to Play Rivian Stock Now. — Barchart
CCJ Public Research Bio
Name: Cameco Corporation. Market class: stock. Public bias: Bear. Public tier: Extended.
Cameco Corporation provides uranium for the generation of electricity in the Americas, Europe, and Asia. It operates in three segments: Uranium, Fuel Services, and Westinghouse. The Uranium segment engages in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its Fuel Services segment is involved in the refining, conve[redacted]on, and fabrication of uranium concentrate, as well as purchase and sale of conve[redacted]on services. The Westinghouse segment operates as a nuclear reactor technology original equipment manufacturer and a provider of products and services to commercial utilities and government agencies. It also provides outage and maintenance, engineering support, instrumentation and controls equipment, and plant modification services, as well as components and parts to nuclear reactors. The company sells its uranium and fuel products and services to nuclear utilities. Cameco Corporation was incor
- Latest public price/reference: $91.21
- Public market capitalization: $39.72B
- Recent public volume/reference: 2.25M
- One-month public movement: -2.02%
- Sector/category: Energy
Why CCJ Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Cameco vs. USA Rare Earth: Which Renewable Energy Stock Is a Better Buy in 2026? — Motley Fool
- Jim Cramer Favors BWX Technologies (BWXT) Over Cameco (CCJ) — Insider Monkey
- Wall Street Analysts Think Cameco (CCJ) Is a Good Investment: Is It? — Zacks
- Russia accuses Ukraine of Zaporizhzhia fuel attack as Odesa strikes continue — Investing.com
UEC Public Research Bio
Name: Uranium Energy Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing of uranium and titanium concentrates properties in the United States, Canada, and the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. The company was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
- Latest public price/reference: $10.18
- Public market capitalization: $5.04B
- Recent public volume/reference: 7.47M
- One-month public movement: -3.05%
- Sector/category: Energy
Why UEC Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Russia accuses Ukraine of Zaporizhzhia fuel attack as Odesa strikes continue — Investing.com
- Is Uranium Energy (UEC) a Buy as Wall Street Analysts Look Optimistic? — Zacks
- BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock? — Motley Fool
- Uranium Energy Rose as Jefferies Started Coverage — GuruFocus.com
CRSP Public Research Bio
Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: Extended.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog
- Latest public price/reference: $51.83
- Public market capitalization: $5.01B
- Recent public volume/reference: 1.25M
- One-month public movement: -2.34%
- Sector/category: Healthcare
Why CRSP Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know — Zacks
- CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It — Zacks
- CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts — MarketBeat
- AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? — Motley Fool
NTLA Public Research Bio
Name: Intellia Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioed[redacted]. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeu
- Latest public price/reference: $11.36
- Public market capitalization: $1.59B
- Recent public volume/reference: 3.97M
- One-month public movement: 0.35%
- Sector/category: Healthcare
Why NTLA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? — Insider Monkey
- FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug — Zacks
- 3 Promising Genomics Stocks in the Spotlight in 2026 — Zacks
- Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform — Stocktwits
COIN Public Research Bio
Name: Coinbase Global, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Coinbase Global, Inc. operates platform for crypto assets in the United States and internationally. It provides the primary financial account in the crypto economy for consumers; a brokerage platform with a pool of liquidity across the crypto marketplace for institutions; and a suite of products granting access to build onchain for developers. The company was founded in 2012 and is based in New York, New York.
- Latest public price/reference: $172.1
- Public market capitalization: $45.41B
- Recent public volume/reference: 18.64M
- One-month public movement: 14.18%
- Sector/category: Financial Services
Why COIN Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- CLARITY Act Hits A Senate Wall: Crypto CEOs Furious, Senators Defend ‘No’ Votes — Some Analysts Say Fight Isn't Over — Stocktwits
- Bitcoin Slides, Crypto Stocks Decline As Trump-Backed CLARITY Act Fails To Pass Senate Vote — Stocktwits
- Landmark Crypto Bill Fails in Key Vote, Casting Doubt on New Rules and Hitting Stocks — The Wall Street Journal
- CLARITY Act setback sends Coinbase, Circle stocks lower — TheStreet
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.